Abstract: Apelin receptor (APLNR) is a crucial G protein-coupled receptor that plays a central role in cardiovascular homeostasis; therefore, it represents a promising therapeutic target for heart failure, myocardial infarction, cardiac hypertrophy, and pulmonary arterial hypertension. However, the activation of APLNR simultaneously engages inhibitory G protein (G_i)-mediated protective signaling and β-arrestin pathways that are associated with pathological cardiac remodeling, thereby imposing significant limitations and challenges for the therapeutic development of conventional balanced agonists. Recent advances in structural biology and pharmacology have provided valuable mechanistic insights into receptor activation and biased signaling. High-resolution cryo-electron microscopy (cryo-EM) structures revealed the conformational basis of signal bias, enabling the rational design of fully G protein-biased agonists that retain cardiovascular benefits while avoiding hypertrophic effects. This review summarizes recent progress in APLNR signaling mechanisms and biased ligand development, highlighting a number of emerging strategies for the precision pharmacological targeting of this receptor.

基于结构开发用于心血管疾病治疗的G蛋白偏向性apelin受体激动剂

[1]Brame AL, Maguire JJ, Yang PR, et al., 2015. Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist. Hypertension, 65(4):834-840.

[2]Chapman FA, Maguire JJ, Newby DE, et al., 2023. Targeting the apelin system for the treatment of cardiovascular diseases. Cardiovasc Res, 119(17):2683-2696.

[3]Chapman FA, Melville V, Godden E, et al., 2024. Cardiovascular and renal effects of apelin in chronic kidney disease: a randomised, double-blind, placebo-controlled, crossover study. Nat Commun, 15:8387.

[4]Cheng SZ, Guo J, Zhou YL, et al., 2026. De novo design of GPCR exoframe modulators. Nature, 651(8104):242-250.

[5]Chng SC, Ho L, Tian J, et al., 2013. ELABELA: a hormone essential for heart development signals via the apelin receptor. Dev Cell, 27(6):672-680.

[6]Choudhury PR, Mishra SK, Yadav S, et al., 2025. In silico peptide design: methods, resources, and role of AI. J Pept Sci, 31(12):e70063.

[7]Dauparas J, Anishchenko I, Bennett N, et al., 2022. Robust deep learning‒based protein sequence design using ProteinMPNN. Science, 378(6615):49-56.

[8]Ekambaram S, Dokholyan NV, 2026. Peptide-based drug design using generative AI. Chem Commun, 62(3):672-691.

[9]Gao SH, Chen HP, 2023. Therapeutic potential of apelin and Elabela in cardiovascular disease. Biomed Pharmacother, 166:115268.

[10]Girault-Sotias PE, Deloux R, de Mota N, et al., 2025. The metabolically resistant apelin-17 analogue LIT01-196 reduces cardiac dysfunction and remodelling in heart failure after myocardial infarction. Can J Cardiol, 41(5):911-924.

[11]Grogan A, Lucero EY, Jiang HR, et al., 2023. Pathophysiology and pharmacology of G protein-coupled receptors in the heart. Cardiovasc Res, 119(5):1117-1129.

[12]Hasheminezhad MM, Mirzad M, Vafa SS, et al., 2025. Early administration of apelin could prevent heart failure following myocardial injury; a systematic review and meta-analysis. Arch Acad Emerg Med, 13(1):e4.

[13]Ji SY, Wang WW, Yang YX, et al., 2026. Dynamic monomer-dimer transition in ligand-induced apelin receptor activation. Nat Commun, 17:4820.

[14]Kinjo T, Higashi H, Uno K, et al., 2021. Apelin/apelin receptor system: molecular characteristics, physiological roles, and prospects as a target for disease prevention and pharmacotherapy. Curr Mol Pharmacol, 14(2):210-219.

[15]Lorente JS, Sokolov AV, Ferguson G, et al., 2025. GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov, 24(6):458-479.

[16]Losano G, Penna C, Cappello S, et al., 2005. Activity of apelin and APJ receptors on myocardial contractility and vasomotor tone. Ital Heart J Suppl, 6(5):272-278.

[17]Marczewski K, Gospodarczyk N, Gospodarczyk A, et al., 2022. Apelin in heart failure. Wiad Lek, 75(10):2501-2506.

[18]Papasergi-Scott MM, Pérez-Hernández G, Batebi H, et al., 2024. Time-resolved cryo-EM of G-protein activation by a GPCR. Nature, 629(8014):1182-1191.

[19]Read C, Nyimanu D, Yang PR, et al., 2021. The G protein biased small molecule apelin agonist CMF-019 is disease modifying in endothelial cell apoptosis in vitro and induces vasodilatation without desensitisation in vivo. Front Pharmacol, 11:588669.

[20]Rettie SA, Campbell KV, Bera AK, et al., 2025a. Cyclic peptide structure prediction and design using AlphaFold2. Nat Commun, 16:4730.

[21]Rettie SA, Juergens D, Adebomi V, et al., 2025b. Accurate de novo design of high-affinity protein-binding macrocycles using deep learning. Nat Chem Biol, 21(12):1948-1956.

[22]Rozwadowski J, Borodzicz-Jażdżyk S, Czarzasta K, et al., 2022. A review of the roles of apelin and ELABELA peptide ligands in cardiovascular disease, including heart failure and hypertension. Med Sci Monit, 28:e938112.

[23]Scharbert L, Strodel B, 2025. Innovative strategies for modeling peptide‒protein interactions and rational peptide drug design. Curr Opin Struct Biol, 93:103083.

[24]Scimia MC, Hurtado C, Ray S, et al., 2012. APJ acts as a dual receptor in cardiac hypertrophy. Nature, 488(7411):394-398.

[25]Seo K, Parikh VN, Ashley EA, 2020. Stretch-induced biased signaling in angiotensin II type 1 and apelin receptors for the mediation of cardiac contractility and hypertrophy. Front Physiol, 11:181.

[26]Sun Q, Tian XW, Tan L, et al., 2025. Multiscale biased chemical space remodeling for developing APLNR agonists with anti-HFpEF efficacy. Proc Natl Acad Sci USA, 122(18):e2423432122.

[27]Tang L, Qiu HL, Xu B, et al., 2024. Microparticle mediated delivery of apelin improves heart function in post myocardial infarction mice. Circ Res, 135(7):777-798.

[28]Tatemoto K, Hosoya M, Habata Y, et al., 1998. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun, 251(2):471-476.

[29]Wang JL, Gareri C, Rockman HA, 2018. G-protein-coupled receptors in heart disease. Circ Res, 123(6):716-735.

[30]Wang WW, Ji SY, Zhang WJ, et al., 2024. Structure-based design of non-hypertrophic apelin receptor modulator. Cell, 187(6):1460-1475.e20.

[31]Watson JL, Juergens D, Bennett NR, et al., 2023. De novo design of protein structure and function with RFdiffusion. Nature, 620(7976):1089-1100.

[32]Yang PR, Read C, Kuc RE, et al., 2019. A novel cyclic biased agonist of the apelin receptor, MM07, is disease modifying in the rat monocrotaline model of pulmonary arterial hypertension. Br J Pharmacol, 176(9):1206-1221.

[33]Yue Y, Liu LE, Wu LJ, et al., 2022. Structural insight into apelin receptor-G protein stoichiometry. Nat Struct Mol Biol, 29(7):688-697.

[34]Yue Y, Liu LE, Wu LJ, et al., 2025a. Structural insights into the regulation of monomeric and dimeric apelin receptor. Nat Commun, 16:310.

[35]Yue Y, Xu CJ, Wu LJ, et al., 2025b. Mechanistic insights into the versatile stoichiometry and biased signaling of the apelin receptor-arrestin complex. Nat Commun, 16:7403.

[36]Zhong JC, Yu XY, Huang Y, et al., 2007. Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice. Cardiovasc Res, 74(3):388-395.